CNBC December 7, 2023
Angelica Peebles

Key Points

– The U.S. Food and Drug Administration is expected to approve exa-cel gene-editing treatment for sickle cell disease.

– Exa-cel would be the first approved medicine in the U.S. to use CRISPR gene-editing technology.

– Vertex Pharmaceuticals and CRISPR Therapeutics co-developed the treatment, which could cost around $2 million per patient.

At age 19, Joe Tsogbe underwent his first hip replacement. In his 20s, he averaged about nine hospitalizations a year. By his 30s, that rose to more than a dozen.

All the result of sickle cell disease, an inherited blood disorder where a genetic mutation causes normally full-moon shaped red blood cells to form into half moons and get stuck inside blood vessels, restricting blood flow...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article